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Abstract
Objectives: To assess the long-term safety and efficacy of a sirolimus-eluting stent with
bioresorbable polymer (BP-SES; Ultimaster), in comparison to a benchmark everolimus-
eluting, permanent polymer stent (PP-EES; Xience), in a prespecified subgroup of patients
with multivessel coronary artery disease (MVD) enrolled in the CENTURY II trial.
Background: The use of coronary stenting in high-risk subgroups, like MVD patients,
is rising. The clinical evidence, including long-term comparative analysis of the effi-
cacy and safety benefits of different new-generation drug eluting stents, however,
remains insufficient.
Methods: Among 1,119 patients (intention-to-treat) enrolled in the CENTURY II
prospective, randomized, single-blind, multicenter trial, a prespecified subgroup of
456 MVD patients were allocated by stratified randomization to treatment with
BP-SES (n = 225) or PP-EES (n = 231). The previously reported primary endpoint of
this study was freedom from target lesion failure (TLF: a composite of cardiac death,
target vessel-related myocardial infarction [MI] and clinically-indicated target lesion
revascularization) at 9 months.
Results: In this MVD substudy, baseline patient, lesion and procedure characteristics
were similar between the treatment arms. At 1 and 5 years, both BP-SES and PP-EES
Abbreviations: (N)IDDM, (non) insulin-dependent diabetes mellitus; (N)STEMI, (non) ST-segment elevation myocardial infarction; ACC/AHA, American College of Cardiology/American Heart
Association; ARC, academic research consortium; BARC, bleeding academic research consortium; BP, bioresorbable-polymer; BP-SES, bioresorbable polymer sirolimus-eluting stent; CABG, coronary
artery bypass graft; CEC, clinical events committee; CI, confidence interval; CTO, chronic total occlusion; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; DMC, data monitoring committee;
ITT, intention-to-treat; MI, myocardial infarction; MVD, multivessel disease; PCI, percutaneous coronary intervention; POCE, patient-oriented composite endpoint; PP, permanent-polymer;
PP-EES, permanent polymer everolimus-eluting stent; ST, stent thrombosis; TLF, target lesion failure; TLR, target lesion revascularization; TV, target vessel; TVF, target vessel failure; TVR, target
vessel revascularization
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displayed low and comparable rates of TLF (5.3 vs. 7.8%; p = .29 and 10.2 vs. 13.4%;
p = .29), and definite or probable stent thrombosis (0.4 vs. 1.3%; p = .33 and 0.9
vs. 1.7%; p = .43), respectively. Composite endpoint of cardiac death and MI, and
patient-oriented composite endpoint of any death, MI, and coronary revasculariza-
tions were also similar.
Conclusions: These results confirm good long-term safety and efficacy of the studied
bioresorbable polymer stent in this high-risk patient population.
K E YWORD S
clinical trials, complex PCI, coronary artery disease, drug eluting, percutaneous coronary
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1 | INTRODUCTION
In recent years, the use of coronary stenting in high-risk subgroups,
like multivessel disease (MVD) patients, has increased. The treatment
of MVD patients, by percutaneous coronary intervention (PCI), how-
ever, is still challenging. These patients usually have more risk factors
and comorbidities (e.g., diabetes), as well as overall less favorable
long-term outcomes. Moreover, the PCI in MVD patients is often
more complex and associates with higher procedural risk.1 Choosing
the most suitable revascularization strategy for MVD patients requires
careful evaluation of both patient and lesion status. The available evi-
dence suggests that in MVD patients without diabetes and/or with
low-anatomical complexity, PCI, and coronary artery bypass grafts
(CABG) achieve similar long-term outcomes with respect to survival and
the composite clinical outcomes. In MVD patients with intermediate-to-
high anatomical complexity, however, evidence from large studies impli-
cates CABG as still the preferred choice over PCI in terms of reducing
mortality and risk of other serious adverse events.2
The application of antiproliferative drugs onto bare metal stent scaf-
folds has improved PCI outcomes with respect to restenosis and the need
for repeat interventions.3,4 Less favorable long-term safety profile, that is,
higher risk of (very) late stent thrombosis (ST),5 however, challenged these
initially promising results. Due to its association with chronic inflammatory
reactions, delayed arterial healing, poor re-endothelialisation and positive
remodeling,6 permanent polymer (PP) coating of first generation drug-
eluting stents (DES) became one of the prime targets for redesign. Conse-
quently, several more advanced drug-carriers were developed, including
bioresorbable polymeric carriers (BP) and biocompatible PP variants, as
well as nonpolymeric stent surfaces.7
In the CENTURY II (Clinical Evaluation of New TerUmo drug-
elUting coRonary stent system in the treatment of patients with coro-
narY artery disease) trial, the Ultimaster sirolimus-eluting BP stent
(BP-SES; with abluminal, gradient polymer coating) was shown to be
noninferior to the Xience PP everolimus-eluting stent (PP-EES; with
circumferential, biocompatible polymer coating) in terms of freedom
from target lesion failure (TLF: a composite of cardiac death, target
vessel-related myocardial infarction [MI] and clinically driven target
lesion revascularization [TLR]), in total study population, at 9 months
follow-up (primary endpoint).8 Good clinical performance of the two
stents was recently confirmed also for the long-term, 5-year follow-
up period.9 In this manuscript, we report the 5-year clinical outcomes
of a subgroup of the original CENTURY II trial, consisting of patients
diagnosed with MVD at the time of randomization.
2 | METHODS
2.1 | Study design and patients
CENTURY II is a prospective, randomized, single-blind, controlled, non-
inferiority, multicentre, clinical trial of BP-SES (Ultimaster, Terumo Cor-
poration, Japan) and PP-EES (Xience, Abbott Vascular; study registra-
tion number: UMIN000006940), involving 58 enrolling centers (see list
in Supporting Information) from Europe, Japan, and South Korea. Out
of 1,119 patients, 456 (40.8%) were diagnosed at the time of study
entry with MVD and during randomization, that was stratified for this
characteristic, allocated to treatment with either BP-SES (n = 225) or
PP-EES (n = 231; Figure 1). MVD was defined as the presence of >50%
diameter stenosis in two or three major epicardial coronary vessels or
bypass grafts (as measured by caliper method or coronary angiography
online). Analysis of this prespecified MVD subgroup was done using
the intention to treat (ITT) approach. Detailed CENTURY II study design
and methods have been described elswhere.8 In brief, patients with
ischemic heart disease due to stenotic lesions of coronary arteries with
reference vessel diameter suitable for treatment with stents ≥2.5
and ≤4.0 mm (≤3.5 mm in Japan) were eligible. Patients were randomly
(1:1) assigned to PCI with either BP-SES or PP-EES. Randomization was
balanced (stratified) for diabetes mellitus, high-risk acute coronary syn-
drome, and MVD. All patients had to provide a signed written informed
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consent. The study complied with the Declaration of Helsinki and was
approved at each participating center by institutional review board and
competent authority of each participating country.
2.2 | Procedures
All coronary interventions were performed according to standard hos-
pital practice, while all postrandomization procedural decisions were
left at operators' discretion. Dual antiplatelet therapy (DAPT) was rec-
ommended for at least 6 months. Clinical follow-up was scheduled at
1, 4, 9 months, and yearly until the final 5-year control visit.
2.3 | Data management and quality assurance
A data monitoring committee (DMC) was responsible for the review
of all data and identification of potential safety issues. An indepen-
dent clinical event committee (CEC) reviewed and adjudicated all
major endpoint-related adverse and bleeding events. All data on case
report forms were 100% verified on-site versus source documents.
Members of DMC and CEC were blinded to patient assignment, while
investigators and study personnel were not.
2.4 | Study devices
Detailed technical description of the Ultimaster (BP-SES) and its' com-
parator device Xience (PP-EES) have been previously reported.8
Briefly, Ultimaster uses a thin strut (80 μm) cobalt-chromium platform,
with an abluminal gradient bioresorbable polymer coating, while
Xience (PP-EES) platform is also based on cobalt-chromium alloy with
PP coating.
2.5 | Endpoints and definitions
The primary endpoint of CENTURY II study was freedom from target
lesion failure (TLF), a device-oriented composite endpoint consisting
of cardiac death, myocardial infarction (MI) not clearly attributable to
a nontarget vessel, and clinically driven target lesion revascularization
(TLR) at 9-months. Secondary outcomes included (a) rate of target
vessel failure (TVF), defined as composite of cardiac death and MI not
clearly attributable to a nontarget vessel, and clinically driven target
vessel revascularization (TVR); (b) patient-oriented composite end-
point (POCE) composed of all deaths, all MI and all coronary revascu-
larizations; (c) composite of cardiac death and MI (d) rates of cardiac
death, MI, TLR, TVR; (e) ST; and (f) rate of bleeding and vascular com-
plications according to Bleeding Academic Research Consortium
(BARC) definitions.10 The endpoints are defined as per Academic
Research Consortium recommendations.11
2.6 | Statistical analysis
The CENTURY II randomized trial was statistically powered for non-
inferiority of BP-SES compared to PP-EES regarding the primary end-
point of freedom from TLF in the total population at 9-months. The
TLF-free rate was 95.64% for BP-SES and 95.09% for PP-EES, dem-
onstrating non-inferiority (p < .0001). Both per-protocol and ITT ana-
lyses gave similar results.8 The present analysis is focused on subset
of MVD patients. Here, categorical variables were compared using the
chi-squared test (for binary variables) and the Cochran–Mantel–
Haenszel test (for multinomial variables). Continuous variables
were compared using nonparametric test (i.e., Mann–Whitney for
two-group comparisons) or Kruskal–Wallis test (for multiple group
F IGURE 1 Study flow chart. Follow-up rates
reflect patients with the completed follow-up visit
or those who died during the follow-up period.
BP-SES, bioresorbable polymer sirolimus-eluting
stent; PP-EES, permanent polymer everolimus-
eluting stent [Color figure can be viewed at
wileyonlinelibrary.com]
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comparison). Dichotomous clinical endpoints were tested using the
chi-squared test. The Kaplan–Meier method was used to estimate
event rates for time-to-event outcomes, while the data were com-
pared using the log-rank test. To explore whether TLF with BP-SES
versus PP-EES was consistent across categories of clinical, procedural,
or lesion characteristics, logistic regression analysis with interaction
testing was performed. All analyses were performed, using the SAS
software, version 9.4 (SAS Institute, Inc., Cary, NC).
3 | RESULTS
3.1 | Patient and procedural characteristics
Four hundered and fifty-six MVD patients were assigned to either
BP-SES (n = 225) or PP-EES (n = 231) treatment-arm (Figure 1). This
subgroup constituted 40.8% of the total study population (n = 1,119).
The mean age was 66 years, with 19% females. A relatively high per-
centage (35%) of diabetes was observed, but this did not differ
between treatment arms. No significant differences in proportion of
cardiac risk factors, mean Charlson comorbidity index, nor in the mean
SYNTAX score were observed among the two treatment arms. Most
of the patients had stable angina, while 27% presented with the high-
risk acute coronary syndrome (ST-segment elevation MI [STEMI] and
non-ST-segment elevation MI [NSTEMI]). On average patients had
2.3 ± 0.5 diseased vessels of which 1.4 ± 0.5 were treated. Overall,
baseline patient characteristics did not differ significantly, aside of the
higher frequency of previous smokers in BP-SES arm (Table 1).
Altogether, 738 lesions, 364 in BP-SES and 374 in PP-EES study-
arm were treated. Mean number of detected lesions per patient was
3.1 ± 1.4, of which 1.6 ± 0.8 were subjected to coronary stenting.
Lesion localization was similar between the study groups. More than
80% of lesions were classified as type B2 or C (ACC/AHA classifica-
tion), while 12.7% represented bifurcation lesion. The frequency of
ostial localization as well as the level of lesion calcification did not dif-
fer between the two treatment arms. Only significantly higher pres-
ence of chronic total occlusion (CTO) lesions was noted in BP-SES
treated patients (Table 2). Regarding the procedural aspects, the fre-
quency of pre- and post-dilatations, and utilized access sites were
similar among the two arms, radial artery being the most frequently
used approach (69.1%). Mean total implanted stent number and the
total length of the implanted stents per patient were 1.9 ± 1.0 and
37.0 ± 21.3 mm, respectively, and were similar among the two arms.
Overall, baseline lesion and procedural characteristics were largely
alike (Table 2).
DAPT at each time point (1 month, 4 months, 9 months, 1-year,
2-year, 3-year, 4-year, and 5-year follow-up) is shown in Table 3. Pro-
portion of patients on DAPT did not differ between the two treat-
ment arms during the entire follow-up period.
3.2 | Medium- and long-term clinical outcomes
Throughout 5-year follow-up period, the rate of TLF composite end-
point was similar among the two treatment arms: 5.3 versus 7.8% at
1-year (p = .29; Table 4) and 10.2 versus 13.4% at 5 years (p = .29;
Table 5) in BP-SES and PP-EES arm, respectively (Figure 2). The TVF
composite endpoint rates were similar in two arms at 1- and 5-years, as
was the incidence of clinically indicated TLR at both time points
(Tables 4 and 5). The incidence of all non-TVR and any revasculari-
zation was significantly higher in PP-EES arm only at 1-year follow-
up (Tables 4 and 5). Rates of cardiac death, MI and definite or
TABLE 1 Baseline patient characteristics
BP-SES
n = 225
PP-EES
n = 231 p Value
Age, years 65.8 ± 10.4 66.9 ± 11.3 .31
Male gender 77.8 84.0 .09
Body mass index, kg/m2 27.3 ± 4.2 26.8 ± 4.2 .27
Silent ischemia 16.4 16.5 .99
Stable angina 48.9 42.9 .20
Unstable angina 12.0 9.1 .31
STEMI 4.9 7.4 .27
NSTEMI 17.8 24.2 .09
Diabetes mellitus, 37.3 33.3 .37
IDDM 21.4 18.2 .61
NIDDM 78.6 81.8 .61
Dyslipidemia 71.0 71.1 .99
Hypertension 74.1 71.2 .49
Smoker, current 19.6 24.3 .23
Smoker, previous 48.9 37.6 .02
Renal insufficiency, 4.0 3.0 .57
Family history of CAD 31.9 32.9 .83
History of PCI 44.4 40.3 .37
History of CABG 7.1 6.5 .79
History of MI 31.1 32.5 .76
Charlson comorbidity index 1.5 ± 1.8 1.3 ± 1.6 .39
Vessels diseased
(LM included)
2.3 ± 0.5 2.3 ± 0.5 .16
Number of vessels diseased
(LM included)
.15
2 75.1 69.3
3 23.6 28.6
4 1.3 2.2
Vessels treated 1.4 ± 0.5 1.4 ± 0.6 .87
Number of vessels treated .76
1 59.6 59.3
2 39.1 38.1
3 1.3 2.6
SYNTAX score 12.7 ± 8.7 12.3 ± 7.6 .91
Note. Values represent either mean ± SD or % of per patient calculation.
Abbreviations: CABG, coronary artery bypass graft; CAD, coronary artery
disease; DAPT, dual anti-platelet therapy; LM, left main coronary artery;
MI, myocardial infarction; (N)IDDM, (non) insulin-dependent diabetes
mellitus; (N)STEMI, (non) ST-segment elevation myocardial infarction; PCI,
percutaneous coronary intervention.
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probable ST, both at mid- and long-term follow-up were alike
(Tables 4 and 5). Notably, the rate of very late ST (0.4%) was identi-
cal in two study arms (Table 5). The composite safety endpoints of
cardiac death and MI and POCE during follow-up are presented in
Figures 3 and 4. At 5-years, rate of cardiac death and MI was 6.7%
in BP-SES arm compared to 10.8% in PP-EES arm (p = .12; Table 5).
Five-year rates of POCE were 27.1% in BP-SES versus 34.2% in
PP-EES (p = .10; Table 5).
At 1 year follow-up, no difference in bleeding rate between the
two groups was noted (Table 4), however, a statistically significant
higher rate of bleeding incidence at 5-years follow-up was observed
in BP-SES arm (Table 5). Finally, the analysis of possible predictors of
TLF, including diabetes, Charlson comorbidity index, Syntax score, and
complete versus incomplete revascularization of the coronary tree is
shown in Figure 5. The risk of TLF after treatment with BP-SES com-
pared with PP-EES did not differ across categories of these predictors
(p for interaction >.05).
4 | DISCUSSION
To the best of our knowledge, the presented data represents unique clin-
ical evidence of long-term safety and efficacy of a bioresorbable polymer
coated sirolimus-eluting stent in the treatment of high risk MVD patients.
This prespecified substudy of the CENTURY II randomized controlled
trial demonstrates a good 5-year performance, both for bioresorbable
(BP-SES) and permanent polymer (PP-EES) system. This is evidenced
by similarly low rates of composite clinical outcomes, like TLF (10.2
vs. 13.4%; p = .29), TVF (14.2 vs. 14.7%; p = .88), cardiac death and MI
(6.7 vs. 10.8%; p = .12), and POCE (27.1 vs. 34.2%; p = .10) up to 5 years
follow-up, in two study arms, respectively. Moreover, relatively low and
comparable TLR, TVR, cardiac death, MI, and definite or probable ST
rates, alongside remarkably low (0.4%) very late ST in both treatment
arms, add to the overall excellent long-term safety and efficacy profile of
the two investigated devices. Although in our study, we observed less
non-TVR in BP-SES versus PP-EES at both 1 year (1.8 vs. 7.4%; p = .005)
and 5 years follow-up (8.4 vs. 14.3%; p = .05), this most likely reflects
the progression of coronary artery disease itself rather than the actual
difference in efficacy between the two compared devices.
Nowadays coronary artery stenting is increasingly being used to treat
the high-risk coronary artery disease patients. Therefore, the evidence of
safety and efficacy benefits of different new-generation DES systems is
needed. The clinical performance and potential benefits of bioresorbable
and permanent (second-generation) drug-carriers has been subjected to
scrutiny in numerous studies. While both systems have been shown to
TABLE 2 Baseline lesion and procedural characteristics
BP-SES
npatients = 225
nlesions = 364
PP-EES
npatients = 231
nlesions=374 p Value
Lesions detected 3.1 ± 1.5 3.1 ± 1.3 .57
Lesions treated 1.6 ± 0.8 1.6 ± 0.8 .93
Lesion location .80
RCA 30.5 32.4
LAD 37.9 34.2
CFX 28.3 30.8
LM 2.5 2.4
Graft 0.8 0.3
Ostial 7.5 9.9 .24
Calcification .32
None/mild 76.2 81.8
Moderate 16.1 11.6
Severe 7.8 6.6
Thrombus present 3.7 3.9 .93
Bifurcation 14.8 10.7 .09
CTO 2.2 0.3 .02
ACC/AHA classification .14
A 3.5 2.8
B1 12.1 16.9
B2 48.9 49.7
C 35.6 30.7
Access site .77
Radial 69.8 68.4
Femoral 28.9 30.3
Brachial 1.3 1.3
Pre-dilatation 76.1 76.2 .97
Post-dilatation 51.0 49.5 .68
Stents implanted per patient 1.9 ± 1.0 2.0 ± 1.1 .30
Total implanted stent
length per patient, mm
36.5 ± 20.1 37.5 ± 22.4 .93
Delivery success per stent 98.3 99.4 .15
Procedure success 97.3 97.8 .73
Note. Values represent either mean ± SD or % of either per patient or per
lesion calculation.
Abbreviations: ACC/AHA, American College of Cardiology/American
Heart Association; CFX, left circumflex coronary artery; CTO, chronic total
occlusion; LAD, left anterior descending coronary artery; LM, left main
coronary artery; RCA, right coronary artery.
TABLE 3 Dual antiplatelet therapy
BP-SES
n = 225
PP-EES
n = 231 p Value
DAPT at 1 month 97.8 (218/223) 98.7 (227/230) .45
DAPT at 4 months 96.4 (215/223) 96.9 (222/229) .75
DAPT at 9 months 85.4 (187/219) 85.0 (187/220) .91
DAPT at 1 year 65.6 (143/218) 62.7 (138/220) .53
DAPT at 2 years 29.9 (64/214) 24.4 (52/213) .20
DAPT at 3 years 20.6 (43/209) 16.9 (35/207) .34
DAPT at 4 years 17.1 (35/205) 14.1 (29/206) .40
DAPT at 5 years 15.0 (30/200) 13.9 (28/201) .76
Note. Values represent % (number) of patients on DAPT at a given
follow-up time-point.
Abbreviation: DAPT, dual antiplatelet therapy.
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associate with better outcomes than first-generation DES,12,13 in recent
years, it has been debated if their long-term clinical performance is compa-
rable or different, and if distinct, in which context benefits can be achieved,
as to provide indication for the use of one over the other system.14
To this end, a consensus is emerging that BP-DES are not inferior
and, in some contexts, may even be more beneficial, than their con-
temporary PP-DES counterparts. This notion, for example, includes
reports of more favorable clinical outcomes of BP-DES in high-risk
STEMI patients.15 The caution, however, needs to be taken when
comparing the performance of various BP- and PP-DES, as due to spe-
cific design differences, they might need to be compared as separate
device entities, rather than as members of larger device families.
Indeed, in their systematic review and network meta-analysis of
TABLE 4 Clinical outcomes at 1-year follow-up
BP-SES
n = 225
PP-EES
n = 231 p Value
All cause death 2.7 (6/225) 2.6 (6/231) .96
Cardiac death 2.2 (5/225) 1.3 (3/231) .45
All MI 2.7 (6/225) 3.5 (8/231) .62
TV-related MI 1.3 (3/225) 2.2 (5/231) .50
Clinically indicated revascularization
Any revascularization 5.8 (13/225) 9.5 (22/231) .13
TLR 2.2 (5/225) 3.9 (9/231) .30
TVR 4.9 (11/225) 5.2 (12/231) .88
Non-TVR 1.3 (3/225) 4.3 (10/231) .05
All revascularizations
Any revascularization 7.6 (17/225) 13.9 (32/231) .03
TLR 3.1 (7/225) 4.3 (10/231) .49
TVR 6.2 (14/225) 6.9 (16/231) .76
Non-TVR 1.8 (4/225) 7.4 (17/231) .005
Composite endpoints
TLF 5.3 (12/225) 7.8 (18/231) .29
TVF 8.0 (18/225) 9.1 (21/231) .68
Cardiac death and MI 4.9 (11/225) 4.8 (11/231) .95
POCE 12.0 (27/225) 18.2 (42/231) .07
Stent thrombosis
Total 0.4 (1/225) 1.3 (3/231) .33
Definite 0.4 (1/225) 1.3 (3/231) .33
Probable 0.0 (0/225) 0.0 (0/231) –
Possible 0.0 (0/225) 0.0 (0/231) –
Definite or probable 0.4 (1/225) 1.3 (3/231) .33
Bleeding or vascular
complications
8.4 (19/225) 11.7 (27/231) .25
Any bleeding 7.6 (17/225) 9.5 (22/231) .45
Bleeding BARC type 2–5 4.9 (11/225) 5.6 (13/231) .72
Bleeding BARC type 3–5 1.8 (4/225) 1.7 (4/231) .97
Note. Values represent % (number); BARC, Bleeding Academic Research
Consortium; MI, myocardial infarction; TLR, target lesion revascularization;
TLF, target lesion failure, defined as composite of cardiac death,
TV-related MI and clinically indicated TLR; TV, target vessel; TVF: target
vessel failure, defined as composite of cardiac death, TV-related MI and
clinically indicated TVR; TVR, target vessel revascularization; POCE,
patient oriented composite endpoint defined as any death, any MI and any
coronary revascularization.
TABLE 5 Clinical outcomes at 5-year follow-up
BP-SES
n = 225
PP-EES
n = 231 p Value
All cause death 9.3 (21/225) 10.8 (25/231) .60
Cardiac death 4.0 (9/225) 5.2 (12/231) .54
All MI 3.1 (7/225) 5.6 (13/231) .19
TV-related MI 1.3 (3/225) 2.6 (6/231) .33
Clinically indicated revascularization
Any revascularization 13.3 (30/225) 13.4 (31/231) .98
TLR 6.2 (14/225) 6.1 (14/231) .94
TVR 10.2 (23/225) 7.8 (18/231) .37
Non-TVR 4.9 (11/225) 6.9 (16/231) .36
All revascularizations
Any revascularization 17.8 (40/225) 22.5 (52/231) .21
TLR 8.4 (19/225) 6.9 (16/231) .54
TVR 13.3 (30/225) 11.3 (26/231) .50
Non-TVR 8.4 (19/225) 14.3 (33/231) .05
Composite endpoints
TLF 10.2 (23/225) 13.4 (31/231) .29
TVF 14.2 (32/225) 14.7 (34/231) .88
Cardiac death and MI 6.7 (15/225) 10.8 (25/231) .12
POCE 27.1 (61/225) 34.2 (79/231) .10
Stent thrombosis
Total 0.9 (2/225) 1.7 (4/231) .43
Definite 0.9 (2/225) 1.7 (4/231) .43
Probable 0.0 (0/225) 0.0 (0/231) –
Possible 0.0 (0/225) 0.0 (0/231) –
Definite or probable 0.9 (2/225) 1.7 (4/231) .43
Stent thrombosis (definite or probable)
Acute 0.0 (0/225) 0.0 (0/231) –
Subacute 0.0 (0/225) 0.9 (2/231) .16
Late 0.4 (1/225) 0.4 (1/231) .99
Very late 0.4 (1/225) 0.4 (1/231) .99
Bleeding or vascular
complications
22.2 (50/225) 15.6 (36/231) .07
Any bleeding 19.6 (44/225) 11.7 (27/231) .02
Bleeding BARC type 2–5 15.1 (34/225) 7.8 (18/231) .01
Bleeding BARC type 3–5 6.7 (15/225) 2.6 (6/231) .04
Note. Values represent % (number); BARC, Bleeding Academic Research
Consortium; MI, myocardial infarction; TLR, target lesion revascularization;
TLF, target lesion failure, defined as composite of cardiac death,
TV-related MI and clinically indicated TLR; TV, target vessel; TVF, target
vessel failure, defined as composite of cardiac death, TV-related MI and
clinically indicated TVR; TVR, target vessel revascularization; POCE,
patient oriented composite endpoint defined as any death, any MI and any
coronary revascularization.
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113 trials (90,584 patients), comparing the clinical performance of
bare metal, bioresorbable-polymer, and permanent-polymer stent
systems, Kang et al. concluded that not only the features of a particu-
lar polymeric carrier itself, but also specific stent alloy and design
aspects, as well as the strut thickness and the used drug, all combined,
may determine the safety of a particular DES system.16
A short bio-resorption time of the drug-eluting polymer, following
stent implantation, should theoretically provide benefits in terms of late
adverse safety events. Nevertheless, a recent meta-analysis of 16 ran-
domized clinical trials (19,886 patients), comparing safety and efficacy
of BP-DES and the second-generation PP-DES systems, reached a
conclusion that both have comparable safety and efficacy profiles.17
Consistently, a recent 5-year follow-up reports of the COMPARE II and
NEXT trials, in which bioresorbable polymer, biolimus-eluting Nobori
stent was compared to the second-generation everolimus-eluting PP-
DES, found no significant differences in relevant safety and efficacy
endpoints, neither at short nor at mid- to long-term follow-up.18,19
While these findings raise questions, whether expected long-term
safety benefits of the BP-DES over PP-DES devices are indeed achiev-
able, further independent trials are needed to evaluate their perfor-
mance, not only in general, but also in specific, more demanding patient
populations.
F IGURE 2 Kaplan–Meier curves of
cumulative event rates of target lesion
failure (TLF) composite endpoint, up until
5-year follow-up. BP-SES, bioresorbable
polymer sirolimus-eluting stent; PP-EES,
permanent polymer everolimus-eluting
stent [Color figure can be viewed at
wileyonlinelibrary.com]
F IGURE 3 Kaplan–Meier curves of
cumulative event rates of cardiac deaths
and myocardial infarction (MI) composite
endpoint, up until 5-year follow-up.
BP-SES, bioresorbable polymer sirolimus-
eluting stent; PP-EES, permanent polymer
everolimus-eluting stent [Color figure can
be viewed at wileyonlinelibrary.com]
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To this end, it is known that treatment of MVD patients poses a sig-
nificant challenge for the contemporary PCI practice, as they associate
with worse clinical prognosis. Findings of the present study demon-
strate excellent mid- to long-term safety and efficacy of the studied
Ultimaster DES in terms of several key clinical outcomes. This data
complements earlier findings of the DISCOVERY 1TO3 trial, where
60 MVD patients were treated with the same DES and nearly complete
strut coverage was noted very early after the initial stent implantation
(within 1–3 months).20 This positive biological response implied a
possibility that Ultimaster BP-SES system could provide beneficial
clinical outcomes in this high-risk patient population. Coupled with the
hypothesis-generating findings of the present study, these observations
warrant further investigation through dedicated, sufficiently powered
trials. Overall, the present study adds to the numerous published
evidence from recent years on excellent performance of Ultimaster
(BP-SES) system. This includes reports of favorable outcomes in general8,9
and specific subpopulations, like STEMI patients,21 bifurcations,22
long lesions,23 and small vessels.24
Our analysis of TLF predictors implies that patient, lesion, and pro-
cedural complexity exert little impact on TLF in the studied context
(Figure 5). Particularly interesting is that relative risk of TLF does not
seem to be impacted by the decision to perform complete over
incomplete coronary tree revascularization. This finding is at odds
with current trends, favoring the complete approach as the more
F IGURE 4 Kaplan–Meier curves of
cumulative event rates of patient-
oriented composite endpoint (POCE), up
until 5-year follow-up. BP-SES,
bioresorbable polymer sirolimus-eluting
stent; PP-EES, permanent polymer
everolimus-eluting stent [Color figure can
be viewed at wileyonlinelibrary.com]
F IGURE 5 Predictors of target lesion failure (TLF): relative risk with 95% confidence interval (CI) of TLF at 5 years. Int. p-value: p-value for
interaction
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optimal modus operandi. Potential explanation could be that physiolog-
ical assessment of stenosis in untreated vessels was determining fac-
tor for deferring revascularization, leading as such to similar
outcomes. Caution, however, needs to be taken with interpretation of
these findings, as they derive from a relatively small study subset of
patients and as such warrant further analysis.
Finally, bleeding rates were comparable at 1 year follow up while a
higher cumulative bleeding incidence was noted in BP-SES treated
MVD patients at 5 years. Considering no difference in DAPT use over
the 5-year follow-up period, a possible explanation can be that higher
proportion of patients with high-risk for bleeding, including prevalence
of oral anticoagulant users, patients with traumas, and/or comorbidities
was acquired through 5 years follow-up in the BP-SES group.
5 | LIMITATIONS
Although MVD patients did constitute a balanced, predefined sub-
group of the CENTURY II trial, this substudy was not powered to
demonstrate non-inferiority of BP-SES to PP-EES. Therefore, herein
presented results are only hypothesis-generating and future studies,
with sufficient power, are needed to corroborate these interesting
findings. Also notable is that the angiographic complexity of MVD
patient in this CENTURY II substudy was relatively low (with baseline
SYNTAX score between 12 and 13 for both groups). Therefore, our
results cannot be extrapolated to all MVD patients seen in everyday
practice, that are treated by either PCI or CABG. Moreover, even
though DMC and CEC members were blinded for patients' assign-
ment, logistical factors prevented blinding of study personnel. While
this factor certainly warrants caution, we believe that its impact on
reported findings should not be significant, as to cast doubt on the
overall conclusions of the study.
6 | CONCLUSION
Our study reveals, that throughout the 5-year follow-up period,
sirolimus-eluting bioresorbable polymer Ultimaster stent (BP-SES), dis-
plays similarly good long-term safety and efficacy profile as the
everolimus-eluting permanent polymer Xience stent (PP-EES), in the
treatment of MVD patients.
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